<?xml version="1.0" encoding="UTF-8" standalone="no"?><document id="DDI-DrugBank.d422">
    <sentence id="DDI-DrugBank.d422.s0" text="Catecholamine-depleting drugs, e.g., reserpine, may have an additive effect when given with beta blocking agents.">
        <entity charOffset="37-45" id="DDI-DrugBank.d422.s0.e0" text="reserpine" type="drug"/>
        <entity charOffset="92-111" id="DDI-DrugBank.d422.s0.e1" text="beta blocking agents" type="group"/>
        <pair ddi="true" e1="DDI-DrugBank.d422.s0.e0" e2="DDI-DrugBank.d422.s0.e1" id="DDI-DrugBank.d422.s0.p0" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d422.s1" text="Patients treated concurrently with BREVIBLOC (esmolol HCl) and a catecholamine depletor should therefore be closely observed for evidence of hypotension or marked bradycardia, which may result in vertigo, syncope, or postural hypotension.">
        <entity charOffset="35-43" id="DDI-DrugBank.d422.s1.e0" text="BREVIBLOC" type="brand"/>
        <entity charOffset="46-56" id="DDI-DrugBank.d422.s1.e1" text="esmolol HCl" type="drug"/>
        <pair ddi="false" e1="DDI-DrugBank.d422.s1.e0" e2="DDI-DrugBank.d422.s1.e1" id="DDI-DrugBank.d422.s1.p0"/>
    </sentence>
    <sentence id="DDI-DrugBank.d422.s2" text="A study of interaction between BREVIBLOC and warfarin showed that concomitant administration of BREVIBLOC and warfarin does not alter warfarin plasma levels.">
        <entity charOffset="31-39" id="DDI-DrugBank.d422.s2.e0" text="BREVIBLOC" type="brand"/>
        <entity charOffset="45-52" id="DDI-DrugBank.d422.s2.e1" text="warfarin" type="drug"/>
        <entity charOffset="96-104" id="DDI-DrugBank.d422.s2.e2" text="BREVIBLOC" type="brand"/>
        <entity charOffset="110-117" id="DDI-DrugBank.d422.s2.e3" text="warfarin" type="drug"/>
        <entity charOffset="134-141" id="DDI-DrugBank.d422.s2.e4" text="warfarin" type="drug"/>
        <pair ddi="false" e1="DDI-DrugBank.d422.s2.e0" e2="DDI-DrugBank.d422.s2.e1" id="DDI-DrugBank.d422.s2.p0"/>
        <pair ddi="false" e1="DDI-DrugBank.d422.s2.e0" e2="DDI-DrugBank.d422.s2.e2" id="DDI-DrugBank.d422.s2.p1"/>
        <pair ddi="false" e1="DDI-DrugBank.d422.s2.e0" e2="DDI-DrugBank.d422.s2.e3" id="DDI-DrugBank.d422.s2.p2"/>
        <pair ddi="false" e1="DDI-DrugBank.d422.s2.e0" e2="DDI-DrugBank.d422.s2.e4" id="DDI-DrugBank.d422.s2.p3"/>
        <pair ddi="false" e1="DDI-DrugBank.d422.s2.e1" e2="DDI-DrugBank.d422.s2.e2" id="DDI-DrugBank.d422.s2.p4"/>
        <pair ddi="false" e1="DDI-DrugBank.d422.s2.e1" e2="DDI-DrugBank.d422.s2.e3" id="DDI-DrugBank.d422.s2.p5"/>
        <pair ddi="false" e1="DDI-DrugBank.d422.s2.e1" e2="DDI-DrugBank.d422.s2.e4" id="DDI-DrugBank.d422.s2.p6"/>
        <pair ddi="false" e1="DDI-DrugBank.d422.s2.e2" e2="DDI-DrugBank.d422.s2.e3" id="DDI-DrugBank.d422.s2.p7"/>
        <pair ddi="false" e1="DDI-DrugBank.d422.s2.e2" e2="DDI-DrugBank.d422.s2.e4" id="DDI-DrugBank.d422.s2.p8"/>
        <pair ddi="false" e1="DDI-DrugBank.d422.s2.e3" e2="DDI-DrugBank.d422.s2.e4" id="DDI-DrugBank.d422.s2.p9"/>
    <negationtags>A study of interaction between BREVIBLOC and warfarin showed that concomitant administration of BREVIBLOC and warfarin does &lt;scope&gt; &lt;cue&gt; not &lt;/cue&gt; alter warfarin plasma levels. &lt;/scope&gt;</negationtags></sentence>
    <sentence id="DDI-DrugBank.d422.s3" text="BREVIBLOC concentrations were equivocally higher when given with warfarin, but this is not likely to be clinically important.">
        <entity charOffset="0-8" id="DDI-DrugBank.d422.s3.e0" text="BREVIBLOC" type="brand"/>
        <entity charOffset="65-72" id="DDI-DrugBank.d422.s3.e1" text="warfarin" type="drug"/>
        <pair ddi="true" e1="DDI-DrugBank.d422.s3.e0" e2="DDI-DrugBank.d422.s3.e1" id="DDI-DrugBank.d422.s3.p0" type="mechanism"/>
    <negationtags>BREVIBLOC concentrations were equivocally higher when given with warfarin, but this is &lt;scope&gt; &lt;cue&gt; not &lt;/cue&gt; likely to be clinically important. &lt;/scope&gt;</negationtags></sentence>
    <sentence id="DDI-DrugBank.d422.s4" text="When digoxin and BREVIBLOC were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in digoxin blood levels at some time points.">
        <entity charOffset="5-11" id="DDI-DrugBank.d422.s4.e0" text="digoxin" type="drug"/>
        <entity charOffset="17-25" id="DDI-DrugBank.d422.s4.e1" text="BREVIBLOC" type="brand"/>
        <entity charOffset="126-132" id="DDI-DrugBank.d422.s4.e2" text="digoxin" type="drug"/>
        <pair ddi="true" e1="DDI-DrugBank.d422.s4.e0" e2="DDI-DrugBank.d422.s4.e1" id="DDI-DrugBank.d422.s4.p0" type="mechanism"/>
        <pair ddi="false" e1="DDI-DrugBank.d422.s4.e0" e2="DDI-DrugBank.d422.s4.e2" id="DDI-DrugBank.d422.s4.p1"/>
        <pair ddi="false" e1="DDI-DrugBank.d422.s4.e1" e2="DDI-DrugBank.d422.s4.e2" id="DDI-DrugBank.d422.s4.p2"/>
    </sentence>
    <sentence id="DDI-DrugBank.d422.s5" text="Digoxin did not affect BREVIBLOC pharmacokinetics.">
        <entity charOffset="0-6" id="DDI-DrugBank.d422.s5.e0" text="Digoxin" type="drug"/>
        <entity charOffset="23-31" id="DDI-DrugBank.d422.s5.e1" text="BREVIBLOC" type="brand"/>
        <pair ddi="false" e1="DDI-DrugBank.d422.s5.e0" e2="DDI-DrugBank.d422.s5.e1" id="DDI-DrugBank.d422.s5.p0"/>
    <negationtags>Digoxin did &lt;scope&gt; &lt;cue&gt; not &lt;/cue&gt; affect BREVIBLOC pharmacokinetics. &lt;/scope&gt;</negationtags></sentence>
    <sentence id="DDI-DrugBank.d422.s6" text="When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.">
        <entity charOffset="17-24" id="DDI-DrugBank.d422.s6.e0" text="morphine" type="drug"/>
        <entity charOffset="30-38" id="DDI-DrugBank.d422.s6.e1" text="BREVIBLOC" type="brand"/>
        <entity charOffset="105-112" id="DDI-DrugBank.d422.s6.e2" text="morphine" type="drug"/>
        <entity charOffset="141-149" id="DDI-DrugBank.d422.s6.e3" text="BREVIBLOC" type="brand"/>
        <entity charOffset="218-225" id="DDI-DrugBank.d422.s6.e4" text="morphine" type="drug"/>
        <pair ddi="false" e1="DDI-DrugBank.d422.s6.e0" e2="DDI-DrugBank.d422.s6.e1" id="DDI-DrugBank.d422.s6.p0"/>
        <pair ddi="false" e1="DDI-DrugBank.d422.s6.e0" e2="DDI-DrugBank.d422.s6.e2" id="DDI-DrugBank.d422.s6.p1"/>
        <pair ddi="false" e1="DDI-DrugBank.d422.s6.e0" e2="DDI-DrugBank.d422.s6.e3" id="DDI-DrugBank.d422.s6.p2"/>
        <pair ddi="false" e1="DDI-DrugBank.d422.s6.e0" e2="DDI-DrugBank.d422.s6.e4" id="DDI-DrugBank.d422.s6.p3"/>
        <pair ddi="false" e1="DDI-DrugBank.d422.s6.e1" e2="DDI-DrugBank.d422.s6.e2" id="DDI-DrugBank.d422.s6.p4"/>
        <pair ddi="false" e1="DDI-DrugBank.d422.s6.e1" e2="DDI-DrugBank.d422.s6.e3" id="DDI-DrugBank.d422.s6.p5"/>
        <pair ddi="false" e1="DDI-DrugBank.d422.s6.e1" e2="DDI-DrugBank.d422.s6.e4" id="DDI-DrugBank.d422.s6.p6"/>
        <pair ddi="false" e1="DDI-DrugBank.d422.s6.e2" e2="DDI-DrugBank.d422.s6.e3" id="DDI-DrugBank.d422.s6.p7"/>
        <pair ddi="false" e1="DDI-DrugBank.d422.s6.e2" e2="DDI-DrugBank.d422.s6.e4" id="DDI-DrugBank.d422.s6.p8"/>
        <pair ddi="true" e1="DDI-DrugBank.d422.s6.e3" e2="DDI-DrugBank.d422.s6.e4" id="DDI-DrugBank.d422.s6.p9" type="mechanism"/>
    <negationtags>When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, &lt;scope&gt; &lt;cue&gt; no &lt;/cue&gt; effect on morphine blood levels was seen, &lt;/scope&gt; but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.</negationtags></sentence>
    <sentence id="DDI-DrugBank.d422.s7" text="No other pharmacokinetic parameters were changed."><negationtags>&lt;scope&gt; &lt;cue&gt; No &lt;/cue&gt; other pharmacokinetic parameters were changed. &lt;/scope&gt;</negationtags></sentence>
    <sentence id="DDI-DrugBank.d422.s8" text="The effect of BREVIBLOC on the duration of succinylcholine-induced neuromuscular blockade was studied in patients undergoing surgery.">
        <entity charOffset="14-22" id="DDI-DrugBank.d422.s8.e0" text="BREVIBLOC" type="drug"/>
        <entity charOffset="43-57" id="DDI-DrugBank.d422.s8.e1" text="succinylcholine" type="drug"/>
        <pair ddi="false" e1="DDI-DrugBank.d422.s8.e0" e2="DDI-DrugBank.d422.s8.e1" id="DDI-DrugBank.d422.s8.p0"/>
    </sentence>
    <sentence id="DDI-DrugBank.d422.s9" text="The onset of neuromuscular blockade by succinylcholine was unaffected by BREVIBLOC, but the duration of neuromuscular blockade was prolonged from 5 minutes to 8 minutes.">
        <entity charOffset="39-53" id="DDI-DrugBank.d422.s9.e0" text="succinylcholine" type="drug"/>
        <entity charOffset="73-81" id="DDI-DrugBank.d422.s9.e1" text="BREVIBLOC" type="brand"/>
        <pair ddi="true" e1="DDI-DrugBank.d422.s9.e0" e2="DDI-DrugBank.d422.s9.e1" id="DDI-DrugBank.d422.s9.p0" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d422.s10" text="Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.">
        <entity charOffset="102-110" id="DDI-DrugBank.d422.s10.e0" text="BREVIBLOC" type="brand"/>
        <entity charOffset="188-194" id="DDI-DrugBank.d422.s10.e1" text="digoxin" type="drug"/>
        <entity charOffset="197-204" id="DDI-DrugBank.d422.s10.e2" text="morphine" type="drug"/>
        <entity charOffset="207-221" id="DDI-DrugBank.d422.s10.e3" text="succinylcholine" type="drug"/>
        <entity charOffset="226-233" id="DDI-DrugBank.d422.s10.e4" text="warfarin" type="drug"/>
        <pair ddi="true" e1="DDI-DrugBank.d422.s10.e0" e2="DDI-DrugBank.d422.s10.e1" id="DDI-DrugBank.d422.s10.p0" type="advise"/>
        <pair ddi="true" e1="DDI-DrugBank.d422.s10.e0" e2="DDI-DrugBank.d422.s10.e2" id="DDI-DrugBank.d422.s10.p1" type="advise"/>
        <pair ddi="true" e1="DDI-DrugBank.d422.s10.e0" e2="DDI-DrugBank.d422.s10.e3" id="DDI-DrugBank.d422.s10.p2" type="advise"/>
        <pair ddi="true" e1="DDI-DrugBank.d422.s10.e0" e2="DDI-DrugBank.d422.s10.e4" id="DDI-DrugBank.d422.s10.p3" type="advise"/>
        <pair ddi="false" e1="DDI-DrugBank.d422.s10.e1" e2="DDI-DrugBank.d422.s10.e2" id="DDI-DrugBank.d422.s10.p4"/>
        <pair ddi="false" e1="DDI-DrugBank.d422.s10.e1" e2="DDI-DrugBank.d422.s10.e3" id="DDI-DrugBank.d422.s10.p5"/>
        <pair ddi="false" e1="DDI-DrugBank.d422.s10.e1" e2="DDI-DrugBank.d422.s10.e4" id="DDI-DrugBank.d422.s10.p6"/>
        <pair ddi="false" e1="DDI-DrugBank.d422.s10.e2" e2="DDI-DrugBank.d422.s10.e3" id="DDI-DrugBank.d422.s10.p7"/>
        <pair ddi="false" e1="DDI-DrugBank.d422.s10.e2" e2="DDI-DrugBank.d422.s10.e4" id="DDI-DrugBank.d422.s10.p8"/>
        <pair ddi="false" e1="DDI-DrugBank.d422.s10.e3" e2="DDI-DrugBank.d422.s10.e4" id="DDI-DrugBank.d422.s10.p9"/>
    <negationtags>Although the interactions observed in these studies do &lt;scope&gt; &lt;cue&gt; not appear &lt;/cue&gt; to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin. &lt;/scope&gt;</negationtags></sentence>
    <sentence id="DDI-DrugBank.d422.s11" text="While taking beta blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic.">
        <entity charOffset="13-25" id="DDI-DrugBank.d422.s11.e0" text="beta blockers" type="group"/>
    </sentence>
    <sentence id="DDI-DrugBank.d422.s12" text="Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction.">
        <entity charOffset="56-66" id="DDI-DrugBank.d422.s12.e0" text="epinephrine" type="drug"/>
    </sentence>
    <sentence id="DDI-DrugBank.d422.s13" text="Caution should be exercised when considering the use of BREVIBLOC and verapamil in patients with depressed myocardial function.">
        <entity charOffset="56-64" id="DDI-DrugBank.d422.s13.e0" text="BREVIBLOC" type="brand"/>
        <entity charOffset="70-78" id="DDI-DrugBank.d422.s13.e1" text="verapamil" type="drug"/>
        <pair ddi="true" e1="DDI-DrugBank.d422.s13.e0" e2="DDI-DrugBank.d422.s13.e1" id="DDI-DrugBank.d422.s13.p0" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d422.s14" text="Fatal cardiac arrests have occurred in patients receiving both drugs."/>
    <sentence id="DDI-DrugBank.d422.s15" text="Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.">
        <entity charOffset="14-22" id="DDI-DrugBank.d422.s15.e0" text="BREVIBLOC" type="brand"/>
        <entity charOffset="158-165" id="DDI-DrugBank.d422.s15.e1" text="dopamine" type="drug"/>
        <entity charOffset="168-178" id="DDI-DrugBank.d422.s15.e2" text="epinephrine" type="drug"/>
        <entity charOffset="185-198" id="DDI-DrugBank.d422.s15.e3" text="norepinephrine" type="drug"/>
        <pair ddi="true" e1="DDI-DrugBank.d422.s15.e0" e2="DDI-DrugBank.d422.s15.e1" id="DDI-DrugBank.d422.s15.p0" type="advise"/>
        <pair ddi="true" e1="DDI-DrugBank.d422.s15.e0" e2="DDI-DrugBank.d422.s15.e2" id="DDI-DrugBank.d422.s15.p1" type="advise"/>
        <pair ddi="true" e1="DDI-DrugBank.d422.s15.e0" e2="DDI-DrugBank.d422.s15.e3" id="DDI-DrugBank.d422.s15.p2" type="advise"/>
        <pair ddi="false" e1="DDI-DrugBank.d422.s15.e1" e2="DDI-DrugBank.d422.s15.e2" id="DDI-DrugBank.d422.s15.p3"/>
        <pair ddi="false" e1="DDI-DrugBank.d422.s15.e1" e2="DDI-DrugBank.d422.s15.e3" id="DDI-DrugBank.d422.s15.p4"/>
        <pair ddi="false" e1="DDI-DrugBank.d422.s15.e2" e2="DDI-DrugBank.d422.s15.e3" id="DDI-DrugBank.d422.s15.p5"/>
    <negationtags>Additionally, BREVIBLOC should &lt;scope&gt; &lt;cue&gt; not &lt;/cue&gt; be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high. &lt;/scope&gt;</negationtags></sentence>
</document>